drugset
drugset / Trial / NCT06415318

TIP Regimen Combined With Triplizumab Neoadjuvant Therapy for Locally Advanced Penile Cancer

NCT06415318 ↗

Phase 2 Recruiting 25 enrolled Sun Yat-sen University
NaSingle-groupOpen-labelTreatment

Summary

Primary Objective: To evaluate the efficacy and safety of TIP (paclitaxel + ifosfamide + cisplatin) combined with Toripalimab as a neoadjuvant treatment in locally advanced penile cancer

Timeline

Start
2024-05-31
Primary completion
2027-06-01
Completion
2027-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Cisplatin Other / unclassified 25 mg/m2 Intravenous
Subject Ifosfamide Small molecule 1.2 g Intravenous
Subject Paclitaxel Small molecule 175 mg/m2 Intravenous
Subject Toripalimab Monoclonal antibody 240 mg Intravenous

Indications

penile carcinoma